Hematology Center

Free consultation

A hematologist can read your blood results before you plan anything

The remote review is free and does not commit you to anything. Send your serial blood count results with their dates, the bone marrow biopsy report if one exists, and any flow cytometry or genetic reports. The reply is written and specific: the likely picture, the missing tests, and whether travel to Istanbul would change your options.

What the Hematology Center treats

Blood diseases sort into two groups that feel nothing alike from the patient's side. On the benign side sit iron deficiency and the other anemias, inherited conditions such as thalassemia and sickle cell disease, immune thrombocytopenia, bleeding disorders including hemophilia and von Willebrand disease, and the clotting tendencies that surface as repeated thromboses and call for a thrombophilia assessment. None of these is a cancer. Several still shorten lives when they are managed casually.

On the malignant side stand the acute leukemias, the chronic leukemias, Hodgkin and non-Hodgkin lymphoma, multiple myeloma, myelodysplastic syndromes and the myeloproliferative neoplasms. Treatment for these is medical rather than surgical: chemotherapy, immunochemotherapy, targeted tablets and supportive care, planned by hematologists and delivered through the hospital's oncology infrastructure, with radiology and nuclear medicine providing imaging, PET included, where lymphoma staging requires it.

Behind both groups works the diagnostic toolkit of a university hematology unit: the hematology laboratory, pathology, flow cytometry, and cytogenetic and molecular testing, with transfusion services carrying patients whose own counts cannot yet carry them.

Three boundaries deserve naming so nobody reads the wrong page. Children with blood diseases are cared for through the hospital's Children's Health center, where pediatric hematology and oncology has its own team. When a disease reaches the point where transplant is the right treatment, in selected leukemias, myeloma or severe inherited anemias, the case moves to the hospital's separate Bone Marrow Transplant Center. And a small group of relapsed B-cell cancers is evaluated for cell therapy at the CAR-T Cell Therapy Center. This page is the front door that comes before all three: diagnosis, medical treatment, and the judgment about which road a given case belongs on.

Reaching a precise diagnosis, and why it decides everything

Lymphoma is a single word for several dozen distinct diseases, and the correct treatment for one of them can be the wrong treatment for its neighbor. Leukemia stretches even wider, from an emergency that needs chemotherapy this week to a condition observed for years without a single tablet. In this specialty the diagnosis is most of the work. A subtype named wrongly costs months, and it can cost treatment lines that do not come back.

A full workup starts smaller than most patients expect. A stained drop of blood under a microscope, the peripheral smear, still directs the first decisions. From there the investigation deepens only as far as the case requires: a bone marrow biopsy to look at where blood is made, flow cytometry to establish exactly which cell population has expanded, and cytogenetic and molecular testing to find the changes that separate one subtype from another and increasingly decide which drug is used.

Why one blood count proves very little

A single blood count is a snapshot. Hemoglobin of 10 means one thing if it measured 14 three months ago, and something far less alarming if it has read 10 for a decade. Trends carry the diagnosis. So the center asks for serial results with their dates instead of the newest printout alone, and a folder of old laboratory reports, however untidy, is worth more than a fresh test taken the day before writing.

This dependence on laboratory work has a practical consequence for anyone living abroad. Very little in hematology turns on physically examining the patient, so a remote second opinion works unusually well here: smear slides and marrow blocks can be re-examined in Istanbul when the original laboratory releases them, written flow cytometry and genetic reports can be reinterpreted exactly as they stand, and whatever questions remain can be listed before anyone considers a flight.

What to send for a remote review

Serial complete blood counts with dates come first. Add the smear and bone marrow reports if a biopsy has been done, together with the slides or blocks when your laboratory will release them, then the flow cytometry, cytogenetic and molecular reports, imaging and PET reports where lymph nodes or the spleen are involved, your current medications, and, for anemia patients, the transfusion record with a rough frequency. A file assembled this way lets a hematologist state in writing what the picture most likely is, which tests are missing, and whether travel would change anything.

When traveling for treatment makes sense, and when it does not

Acute leukemia is the exception to everything else on this page. When a blood picture suggests it, with blasts on the smear and normal counts failing, treatment should begin within days at the nearest hospital able to deliver it. Visa applications, flight searches and second opinions all take longer than this disease allows. A serious center does not encourage that patient to board a plane first, and this one does not.

Travel fits three other situations well. There is the abnormal count that has gone months without a name, where a short, dense diagnostic visit can settle in days what has drifted for half a year. There is the chronic disease standing at a decision point: a CML response that needs assessing, an early CLL where observation and treatment are being weighed, a myeloma where the next line has to be chosen. And there is the planned treatment course whose timing is elective, where cycles can be scheduled around flights and a stay in Istanbul instead of against them.

Triage of this kind is the first thing the free file review does, and sometimes the written answer is that traveling now would be a mistake. That answer costs nothing. It can matter more than any other on this page.

Chronic blood diseases, and what managing them well looks like

Some leukemias are now managed the way high blood pressure is. A Swedish registry analysis published in the Journal of Clinical Oncology in 2016 found that life expectancy in chronic myeloid leukemia, treated with modern targeted tablets, approaches that of the general population, especially for younger patients [1]. A sentence like that could not have been written twenty years ago. It changes what a sensible cross-border care plan looks like: less drama, more structure.

Chronic myeloid leukemia: a tablet and a monitoring calendar

CML treatment is a daily tablet plus scheduled blood tests that measure the disease at the molecular level, down to fractions of a percent. What an international patient needs from Istanbul is rarely the tablet itself, which most countries stock. It is the structure around it: confirmation that the current drug is still the right one, a written monitoring calendar a local laboratory can run, defined thresholds that would trigger a change of drug, and remote review of the results as they arrive. Repeated flights add nothing to such a plan. Built properly, it runs at home.

Chronic lymphocytic leukemia: when the right treatment is none yet

Hearing 'no treatment yet' can feel like being turned away. In early CLL it is correct care. International iwCLL guidelines published in Blood in 2018 define when treatment should start, naming criteria such as progressive marrow failure, rapidly rising lymphocyte counts and symptomatic enlargement of nodes or spleen, and they direct doctors to observe patients who meet none of them, because starting earlier has not been shown to lengthen life [2]. Observation is a plan with appointments, thresholds and scheduled counts, not the absence of a plan. A second opinion that confirms watch and wait is a legitimate outcome of a file review, and for some readers it is the most valuable one available.

Thalassemia: a structured review for a lifelong disease

Thalassemia concentrates in the Mediterranean, the Middle East and Asia, which is to say in the regions many readers of this site live in. A 2018 Lancet seminar describes the modern shape of care: regular transfusion programs, iron chelation to remove the iron those transfusions leave behind, and curative options reserved for selected, usually younger patients [3]. A structured assessment at the Hematology Center goes through the transfusion history, measures the iron burden, asks whether the chelation regimen still fits it, and screens for the heart, liver and endocrine complications that accumulating iron causes. Plenty of long-transfused adults have never had that full accounting done in one place, and it is a realistic reason to travel once, calmly, at a time of their choosing.

How the center works with a patient who lives abroad

Every international case follows the same spine, whatever the disease behind it.

Not every file ends in an invitation. When the honest reading is that nothing in Istanbul would improve on the care already available at home, the written reply says exactly that, and the reader has lost nothing by asking.

What blood disease treatment costs in Turkey

No single number covers a specialty that runs from an iron infusion to months of chemotherapy. Listing platforms such as Bookimed give an orientation for Turkey as a market: hematologist consultations around 120 to 180 dollars, basic blood panels near 100 dollars, a bone marrow biopsy listed anywhere from roughly 1,200 to 2,600 dollars depending on the clinic, and full chemotherapy courses spanning about 17,000 to 45,000 dollars, with intensive induction courses toward the top of that range. These are third-party figures compiled from listings, and they are context rather than quotes.

What actually moves the price is knowable in advance. Whether the visit is a diagnostic workup or a treatment course. How many chemotherapy or immunotherapy cycles the plan contains and which drugs are inside them, since modern antibody drugs cost several times what older chemotherapy does. Whether cycles run as hospital admissions or as outpatient visits. How much growth factor and transfusion support the blood counts demand along the way. And how wide the molecular test panel has to be for this particular disease.

Biruni Hospital prices each case individually, in writing, after the free file review, so the figure arrives attached to a named diagnosis and a counted number of cycles. A price quoted before those two things are known describes some other patient.

Questions international patients ask about blood disease care

References

1. Bower H, Bjorkholm M, et al. Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. Journal of Clinical Oncology. 2016;34(24):2851-2857.
2. Hallek M, Cheson BD, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745-2760.
3. Taher AT, Weatherall DJ, Cappellini MD. Thalassaemia. The Lancet. 2018;391(10116):155-167.